摘要
目的:探究孟鲁司特钠联合布地奈德治疗小儿哮喘的临床疗效及安全性.方法:选取我院2017年2月—2018年2月收治的84例小儿哮喘患儿,依据治疗方法的不同分为两组,甲组予以吸入用布地奈德混悬液(年龄≥4岁,剂量为0.4 mg/次,每隔6 h用药一次;若年龄<4岁,剂量为0.2 mg/次,每隔6 h用药一次)治疗,乙组在甲组基础上联用孟鲁司特钠颗粒(年龄≥6岁,剂量为5 mg,qd;年龄<6岁,剂量为4 mg,qd),比较两组疗效.结果:乙组治疗总有效率为97.62%,高于甲组的80.95%,差异有统计学意义(P<0.05);治疗后乙组T淋巴细胞亚群值、NK百分比均优于甲组,差异有统计学意义(P<0.05);乙组峰值呼气流速(PEF)、第1s用力呼气末容积(FEV1)高于甲组,嗜酸性粒细胞(Eos)低于甲组,差异有统计学意义(P<0.05);乙组不良反应发生率为4.8%,低于甲组的26.2%,差异有统计学意义(P<0.05).结论:孟鲁司特钠联合布地奈德治疗小儿哮喘的疗效显著,能够改善患儿的肺功能,降低机体炎症反应,且安全性较高,值得临床进一步推广应用.
Objective:explore the clinical efficacy and safety of montelukast sodium combined with budesonide in the treatment of pediatric asthma.Methods:84 children with pediatric asthma admitted to our hospital from February 2017 to February 2018 were selected and divided into two groups according to different treatment methods.The children in the group A were given budesonide suspension for inhalation(age≥4 years old,dosage:0.4 mg/time,once every 6 h;age<4 years old,dosage:0.2 mg/time,once every 6 h),and the children in the group B were further treated with montelukast sodium granules(age≥6 years old,dosage:5 mg,qd;age<6 years old,dosage:4 mg,qd).The efficacy was compared between the two groups.Results:The total effective rate of the treatment in the group B was 97.62%,which was higher than 80.95%in the group A,and the difference was statistically significant(P<0.05).After treatment,the value of T lymphocyte subsets and the percentage of NK in the group B were better than those in the group A,and the differences were statistically significant(P<0.05).The peak expiratory flow rate(PEF)and forced end expiratory volume in one second(FEV1)in the group B were higher than those in the group A,and the number of eosinophils(Eos)in the group B was lower than that in the group A,with statistically significant differences(P<0.05).The incidence of adverse reactions in the group B was 4.8%,which was lower than 26.2%in the group A,and the difference was statistically significant(P<0.05).Conclusion:Montelukast sodium combined with budesonide has a significant therapeutic effect on pediatric asthma,and can improve the lung functions of the children and reduce inflammatory response,and has high safety,which is worthy of further popularization and clinical application.
作者
刘俊
赵庆贺
徐豪杰
Liu Jun;Zhao Qing-he;Xu Hao-jie(The Third Affiliated Hospital of Zhengzhou University,Zhengzhou Henan 450000,China)
出处
《中国合理用药探索》
CAS
2019年第6期87-89,共3页
Chinese Journal of Rational Drug Use
